PYRGF vs. TNGX, CMRX, BTMD, SNDL, TRVI, LFVN, VYGR, YMAB, ITOS, and IMMP
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Tango Therapeutics (TNGX), Chimerix (CMRX), biote (BTMD), SNDL (SNDL), Trevi Therapeutics (TRVI), LifeVantage (LFVN), Voyager Therapeutics (VYGR), Y-mAbs Therapeutics (YMAB), iTeos Therapeutics (ITOS), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs.
Tango Therapeutics (NASDAQ:TNGX) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.
Tango Therapeutics received 28 more outperform votes than PyroGenesis Canada when rated by MarketBeat users.
PyroGenesis Canada has lower revenue, but higher earnings than Tango Therapeutics. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tango Therapeutics currently has a consensus price target of $13.14, suggesting a potential upside of 361.15%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than PyroGenesis Canada.
PyroGenesis Canada has a net margin of -115.14% compared to Tango Therapeutics' net margin of -284.42%. PyroGenesis Canada's return on equity of 0.00% beat Tango Therapeutics' return on equity.
In the previous week, PyroGenesis Canada had 3 more articles in the media than Tango Therapeutics. MarketBeat recorded 3 mentions for PyroGenesis Canada and 0 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.
79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 6.3% of Tango Therapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Tango Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.
Summary
Tango Therapeutics beats PyroGenesis Canada on 9 of the 15 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 1/21/2025 by MarketBeat.com Staff
Free PYRGF Stock Alerts